瘤中的CD39 (ENTPD1):一种潜在的治疗标和预后生物标志物

Cuicui Li1, Litian Zhang1, Qiqi Jin1

  • 1Department of Hematology, Lanzhou University Second Hospital, Lanzhou, 730000, China.

Biomarkers in medicine
|September 15, 2023
PubMed
概括

通过调节瘤微环境中的免疫细胞功能,CD39核糖酶阻碍了抗癌免疫力. 向CD39对癌症治疗和预测免疫疗法反应有希望.